Plasma transforming growth factor-β1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma

Cancer

Volumn 86, Issue 9, 1999, Pages 1712-1719

  Kong, Fengming ^a   Jirtle, Randy L ^a   Huang, Dale H ^a   Clough, Robert W ^a   Anscher, Mitchell S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Lung carcinoma; Prognosis; Radiotherapy; Transforming growth factor ; Tumor marker

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKER;

ADULT; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKERS, BIOLOGICAL;

EID: 0033229730     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19991101)86:9<1712::AID-CNCR12>3.0.CO;2-V     Document Type: Article

References (53)

1. Ginsberg R, Yokes E, Raben A. Lung cancer. In: Devita VT Jr., Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. Philadelphia: Uppincott-Raven, 1997: 858-911.
2. Mountain C. New prognostic factors in lung cancer: biologic prophets of cancer cell aggression. Chest 1995;108:246-54.
3. Arteaga C, Dugger T, Winnier A, Forbes J. Evidence for a positive role of transforming growth factor-beta in human breast cancer cell tumorigenesis. J Cell Biochem Suppl 1993; 17G:187-93.
4. Jasani B, Wyllie F, Wright P, Lemoine N, Williams E, Wynford-Thomas D. Immunocytochemically detectable TGF-β associated with malignancy in thyroid epithelial neoplasia. Growth Factors 1990;2:149-55.
5. Denholm E, Rollins S. Expression and secretion of transforming growth factor β by bleomycin-stimulated rat alveolar macrophages. Am J Physiol 1993;264:L36-L42.
6. Derynck R, Goeddel D, Ullrich A, Gutterman J, Williams R, Bringman T, et al. Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors. Cancer Res 1987; 47:707-12.
7. Ito N, Kawata S, Tamura S, Takaishi K, Shirai Y, Kiso S, et al. Elevated levels of transforming growth factor β messenger RNA and its polypeptide in human hepatocellular carcinoma. Cancer Res 1991;51:4080-3.
8. Shirai Y, Kawata S, Ito N, Tamura S, Takaishi K, Kiso S, et al. Elevated levels of plasma transforming growth factor-β in patients with hepatocellular carcinoma. Jpn J Cancer Res 1992;83:676-9.
9. Shirai Y, Kawata S, Tamura S, Ito N, Tsushima H, Takaishi K, et al. Plasma transforming growth factor-b1 in patients with hepatocellular carcinoma: comparison with chronic liver diseases. Cancer 1994;73:2275-9.
10. Ivanovic V, Melman A, Davis-Joseph B, Valcic M, Geliebter J. Elevated plasma levels of TGFβ1 in patients with invasive prostate cancer. Nat Med 1995;1:282-3.
11. Kong F-M, Jirtle R, Anscher M. Changes in plasma TGFβ levels in prostate cancer patients during radiotherapy may help select patients for adjuvant hormonal treatment. Int J Radiat Oncol Biol Phys 1996;36(Suppl 1):376.
12. Kong F-M, Anscher M, Jirtle R. Tumor marker protocols: plasma transforming growth factor beta, a plasma tumor marker. In: Hannausek M, Walaszek Z, editors. Methods in molecular medicine. Totowa, NJ: Humana Press, Inc., 1998: 417-30.
13. Kong F-M, Anscher M, Xiong Z, Jirtle R. Elevated circulating transforming growth factor betal levels decreased after radiotherapy in patients with lung cancer, cervical cancer and Hodgkin's disease: a possible tumor marker. Int J Radiat Oncol Biol Phys 1995;32(Suppl 1):239.
14. Wakefield L, Letterio J, Chen T, Danielpour D, Allison R, Pai L, et al. Transforming growth factor-β1 circulates in normal human plasma and is unchanged in advanced breast cancer. Clin Cancer Res 1995;1:129-36.
15. Kong F-M, Washington MK, Jirtle RL, Anscher MS. Plasma transforming growth factor β1 reflects disease status in patients with lung cancer after radiotherapy: a possible tumor marker. Lung Cancer 1996;16:47-59.
16. Kong FM, Anscher MS, Abbott B, Murase T, Iglehart JD, Jirtle RL. Elevated plasma TGFβ1 levels in breast cancer patients decrease following removal of the tumor. Ann Surg 1995; 222:155-62.
17. Beahrs OH, Henson DE, Hulter RVP, Myers MH. American Joint Committee on Cancer manual for staging of cancer. 4th ed. Philadelphia: J. B. Lippincott Co., 1992.
18. Brown R, Chirala R. Utility of microwave-citrate antigen retrieval in diagnostic immunohistochemistry. Mod Pathol 1995;8(5):515-20.
19. Lawrence D. Identification and activation of latent transforming growth factor β. Methods Enzymol 1991;198:327-36.
20. Barcellos-Hoff M, Dix T. Redox-mediated activation of latent transforming growth factor-β1. Mol Endocrinol 1996;10: 1077-83.
21. Lyons RM, Gentry LE, Purchio AF, Moses HL. Mechanism of activation of latent recombinant transforming growth factor β1 by plasmin. J Cell Biol 1990;110:1361-7.
22. Roberts A, Sporn M. Transforming growth factor β. Adv Cancer Res 1988;51:107-45.
23. Anscher MS, Peters WP, Reisenbichler H, Petros WP, Jirtle RL. Transforming growth factor β as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. N Engl J Med 1993;328:1592-8.
24. Anscher MS, Kong F-M, Murase T, Jirtle RL. Normal tissue injury after cancer therapy is a local manifestation of a systemic condition. Br J Radiol 1995;68:331-3.
25. Anscher MS, Kong F-M, Marks LB, Bentel GC, Jirtle RL Changes in plasma transforming growth factor beta during radiotherapy and the risk of symptomatic radiation-induced pneumonitis. Int J Radiat Oncol Biol Phys 1997;37:253-8.
26. Boyd F, Massague J. Transforming growth factor-β inhibition of epithelial cell proliferation linked to the expression of a 53-kDa membrane receptor. J Biol Chem 1989;264:2272-8.
27. Frater-Schroder M, Muller G, Birchmeier W, Bohlen P. Transforming growth factor -beta inhibits endothelial cell proliferation. Biochem Biophys Res Commun 1986;137:295-302.
28. Fynan T, Reiss M. Resistance to inhibition of cell growth by transforming growth factor-beta and its role in oncogenesis. Crit Rev Oncog 1993;4:493-540.
29. Kerbel R. Expression of multi-cytokine resistance and multigrowth factor independence in advanced cancer: malignant melanoma as a paradigm. Am J Pathol 1992;141:519-24.
30. Mulder K, Ramey M, Hoosein N, Levine AE, Hinshaw X, Brattain D, et al. Characterization of transforming growth factor-beta-resistant subclones isolated from a transforming growth factor-beta-sensitive human colon carcinoma cell line. Cancer Res 1988;48:7120-5.
31. Friedman E, Gold L, Klimstra D, Zeng Z, Winawer S, Cohen A. High levels of transforming growth factor beta 1 correlate with disease progression in human colon cancer. Cancer Epidemiol Biomarkers Prev 1995;4:549-54.
32. Morgan D, Edman J, Standring D, Fried V, Smith M, Roth R, et al. Insulin-like growth factor II receptor as a multifunctional binding protein. Nature 1987;329:301-7.
33. Kornfeld S. Structure and function of the mannose 6-phosphate/insulin-like growth factor II receptors. Annu Rev Biochem 1992;61:307-30.
34. Dennis P, Rifkin D. Cellular activation of latent transforming growth factor β requires binding to the cation-independent mannose 6-phosphate/insulin-like growth factor type II receptor. Proc Natl Acad Sci USA 1991;88:580-4.
35. 4-exposed rat fat-storing cells and facilitates activation of latent transforming growth factor-β in cocultures with sinusoidal endothelial cells. Hepatology 1995;21:1429-37.
36. Sporn M, Roberts A. Transforming growth factor-β: multiple actions and potential clinical applications. JAMA 1989;262: 938-41.
37. Hankins G, De Souza A, Bentley R, Patel M, Marks J, Iglehart J, et al. M6P/IGF2 receptor: a candidate breast tumor suppressor gene. Oncogene 1996;12:2003-9.
38. Devine P, Rachel J. Use of plasma in serum tumour marker assays: cancer-associated serum antigen and mammary serum antigen. Eur J Clin Chem Clin Biochem 1994;32:629-30.
39. Norgaard P, Hougaard S, Poulsen H, Spang-Thomsen M. Transforming growth factor β in cancer. Cancer Treat Rev 1995;21:367-403.
40. Ahuja S, Paliogianni F, Yamada H, Balow J, Boumpas D. Effect of transforming growth factor-β on early and late activation events in human T-cells. J Immunol 1993;150: 3109-18.
41. Weller M, Fontana A. The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain. Brain Res Rev 1995;21:128-51.
42. Wahl S, Hunt D, Wong H, Dougherty S, McCartney-Francis N, Wahl L, et al. Transforming growth factor beta is a potent immunosuppressive agent which inhibits interleukin-1 dependent lymphocyte proliferation. J Immunol 1988;140: 3026-32.
43. Border W, Brees D, Noble N. Transforming growth factor-beta and extracellular matrix deposition in the kidney. Contrib Nephrol 1994;107:140-5.
44. Bruijn J, Roos A, De Geus B, De Heer E. Transforming growth factor-beta and the glomerular extracellular matrix in renal pathology. J Lab Clin Med 1994;123(1):34-47.
45. Flaumenhaft R, Rifkin D. Extracellular matrix regulation of growth factor and protease activity. Curr Opin Cell Biol 1991;3:817-23.
46. Merwin J, Anderson J, Kocher O, van Itallie C, Madri J. Transforming growth factor beta 1 modulates extracellular matrix organization and cell-cell junctional complex formation during in vitro angiogenesis. J Cell Physiol 1990;142: 117-28.
47. Koh G, Kim S, Klug M, Park K, Soonpaa M, Field L. Targeted expression of transforming growth factor-beta 1 in intracardiac grafts promotes vascular endothelial cell DNA synthesis. J Clin Invest 1995;95:114-21.
48. Pepper M, Vassalli J, Orci L, Montesano R. Biphasic effect of transforming growth factor-β1 on in vitro angiogenesis. Exp Cell Res 1993;204:356-63.
49. Iruela-Arispe M, Sage E. Endothelial cells exhibiting angiogenesis in vitro proliferate in response to TGFβ1. J Cell Biochem 1993;52:414-30.
50. Agrotis A, Bobit A. Vascular remodeling and molecular biology: new concepts and therapeutic possibilities. Clin Exp Pharm Physiol 1996;23:363-8.
51. Bikfalvi A. Significance of angiogenesis in tumour progression and metastasis. Eur J Cancer 1995;31A(7-8):1101-4.
52. Phillips G, Whitehead R, Stone A, Ruebel M, Goodkin M, Knighton D. Transforming growth factor beta (TGF-B) stimulation of angiogenesis: an electron microscopic study. J Submicrosc Cytol Pathol 1993;25:149-55.
53. Anscher M, Kong F, Andrews K, Clough R, Marks L, Bentel G, et al. Plasma transforming growth factor β1 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys 1998;41: 1029-36.